Trial Profile
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Single-arm Phase II Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 01 May 2023 Planned End Date changed from 1 Dec 2037 to 1 Dec 2041.
- 01 May 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Apr 2024.
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress